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1. Introduction 
In previous communications, we [l] described the 
use of Sepharose-linked binding proteins for a con- 
venient and precise assay of cycle-3’,5’-adenosine 
monophosphate (CAMP) according to the principle of 
competitive protein binding (CPB) between unlabelled 
and labelled CAMP. The method had the advantage 
of allowing a simple and rapid separation of “bound” 
from “free” radioactive CAMP by mere filtration of 
the “immobilized” protein linked to the Sepharose. 
It avoided all the difficulties arising with soluble 
CAMP binding proteins that had been in use hitherto 
(for references see [l] ). 
It occurred to us that similar improvements could 
possibly be achieved for the CPB assays of plasma 
testosterone. In a collaborative effort, we succeeded 
in devising an equally convenient and precise testo- 
sterone assay using Sepharose-linked testosterone 
binding proteins from human late pregnancy serum. 
2. Materials and methods 
Water was deionized and twice distilled before use. 
For measuring aqueous solutions, we used Oxford, for 
solutions in organic solvents, glass pipettes. Buffer I: 
0.1 N NaHCO,/O. 1 N NaCl; buffer II: 0.05 M Tris- 
HCl, pH 7.4. 
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2.1. Sepharose-linked testosterone binding proteins 
3 g of Sepharose activated with cyanogen bromide 
(purchased from Pharmacia or prepared according to 
[ 11) were suspended in 10 ml of buffer I and kept 
for 20 rnin at room temp. The gel was transferred to 
a porous glass filtration funnel and washed for not 
more than 15 min with approx. 200 ml of 0.001 N 
HCl to remove soluble impurities. The material on the 
filter was then washed with approx. 200 ml of buffer 
I, sucked almost dry, and transferred to a solution of 
2 ml of human late pregnancy serum (third trimester) 
in 5 ml of buffer I contained in a 100 ml round bot- 
tomed flask. The mixture was gently stirred by slow 
rotation of the flask at 4” for 15 hr. The protein- 
modified Sepharose was collected on a porous glass 
filter and washed with 250-500 ml of buffer I, fol- 
lowed by 250-500 ml of buffer II. The gel was then 
suspended in 200 ml of buffer II and stored until 
used at approx. l-4’ in a beaker sealed with “Para- 
film”. 
2.2. Assay of “testosterone-like substances” in blood 
plasma 
2.2.1. Preparation of plasma extracts and blanks 
The heparinized blood was immediately centrifuged 
and the plasma stored at -20” in plastic vials. 1.0 ml 
of the plasma (or a smaller amount diluted to 1.0 ml 
with water) was placed, together with 5.0 ml of 
spectroscopic grade dichloromethane, into a glass- 
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stoppered vial and agitated for 1 min. The aqueous 
phase was pipetted off and replaced with 0.5 ml 1 N 
Na,CO, solution. After agitation (30 set) and centri- 
fugation, the aqueous phase was removed, and the 
organic phase washed neutral with two to three 
successive 0.75 ml volumes of water (test with pH 
paper). Four 0.50 ml aliquots of the organic phase 
were pipetted into four Eppendorf vials and kept in 
a vacuum desiccator for at least 1 hr at approx. 10 Torr 
For the estimation of blank values, 1.0 ml of water 
was treated in exactly the same manner as the plasma 
samples. 
2.2.2. Calibration 
For every assay (double estimations of the 
unknowns) a calibration curve was constructed, using 
50 ~1 each of ethanolic solutions containing in this 
volume 5.0, 1.25, 0.32, 0.008, and zero ng of 
testosterone in Eppendorf vials. The solvent was 
removed as in sect. 2.2.1. 
2.2.3. Binding assay 
100 ~1 of [ 1 ,2-3H] testosterone (Amersham) in 
water (= 10 nCi) were added to each of the desiccated 
vials (mechanical shaking for 30 set dissolved the 
dried extract or blank). The protein-modified Sephar- 
ose in the storage beaker was evenly suspended by 
slow magnetic stirring, and 200 ~1 each of the 
suspension pipetted into the vials. After mechanical 
agitation for 5 set, equilibration was achieved by 
standing at room temp. for unspecified times between 
20 and 120 min. The contents of the vials were then 
pipetted onto 35 pm polyester nets (Mtillereigaze Estal 
mono PE 35, No. 19 176, Schweizerische Seidegaze- 
fabrik AG., Thal, Switzerland) contained in suction 
filter funnels. The vials were rinsed with 1 ml each of 
buffer II, and the materials on the filters washed once 
or twice with approx. 1 ml of the same buffer 
(volumes aren’t critical). The nets were transferred 
into the counting vials and covered with 5 ml of the 
scintillant solution (Insta-Gel, Packard). After agita- 
tion, the radioactivity was determined by scintillation 
counting (Packard Tri-Carb instrument). It was usually 
expressed in percentage of a 100% value (= 100 1.11 of
the above [ 1 ,2-3H] testosterone solution added to the 
scintillant). 
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3. Results 
3.1. Properties of the “Sepharose-linked testosterone 
binding proteins ” 
The mean association constant for [ 1 ,2-3H] testo- 
sterone in 33 mM Tris-HCl buffer, pH 7.4, at 20”, and 
the Hill coefficients, n, were determined according to 
the method described in [ 11: K,, = 9.87 X 1 O* l/mole 
(K,, = 1.01 X 10e9 mole/l); n = 1. The non-specific 
adsorption of [ 1 ,2-3H]testosterone to Sepharose and 
to the polyester net is less than 1% of the total tracer 
concentration added. 
3.2. Water blank 
The water blank is considerably lower with the 
present method (K = 6.8 ng/lOO ml, S, = 2.2, n = 5) 
than with Florisi12 (X = 64.6 ng/lOO ml, S, = 4.6, 
n = 13). In both cases, the extraction was carried out 
with dichloromethane, the solvent giving the lowest 
“reagent blank” [3]. 
3.3. Plasma testosterone values 
Results obtained with the present method from 
samples of normal subjects and patients with various 
Table 1 
Plasma testosterone values in normal pubertal and adult males. 
Subject No. Age 
(Yr) 
Plasma 
testosterone 
(rig/l 00 ml) 
1 15 644 
2 16 680 
3 16 685 
4 17 410 
1000* 
1025* 
1300* 
5 17 465 
6 17 470 
7 19 530 
8 20 800 
9 21 455 
10 54 980 
Mean value + s 612 r 172 
* = 2,4 and 6 days after administration of human chorionic 
gonadoptropin (5000 U per square meter of body surface area). 
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Table 2 
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Plasma testosterone values in patients with various disorders. 
Subject No. -be 
(YI) 
Sex Diagnosis 
Plasma 
testosterone 
(rig/100 ml) 
High values 
1 
2 
3 
8 30 F 
Low values 
9 0.6 M 
10 4 M 
11 6 M 
12 52 M 
13 16 M 
14 16 M 
15 17 M 
16 17 M 
17 18 M 
18 19 M 
19 17 M 
20 35 M 
21 40 M 
19 
23 F 
23 F 
30 F 
27 M 
M 
M 
M 
Idiopathic precocious 
puberty, untreated 
Idiopathic precious 
puberty untreated 
Under treatment with 
cyproterone acetate 
Testicular teratoma, 
untreated 
After surgery 
Idiopathic hirsutism 
Idiopathic hirsutism 
Idiopathic hirsutism 
Congenital adrenal 
hyperplasia (21-hydroxyl- 
ase deficiency), untreated 
Virilizing adenoma of the 
left adrenal: 
Left adrenal venous plasma 
Right adrenal venous plasma 
Tall stature within normal limits 
Hereditary defect of testosterone 
biosynthesis (17,20desmolase 
deficiency) 
Congenital anorchia 
Castrate, untreated 
Delayed puberty 
Delayed puberty 
Delayed puberty 
Delayed puberty 
Delayed puberty 
Delayed puberty 
Klinefelter’s syndrome 
Hypogonadism 
Hypogonadism 
750 
1140 
410 
600 
235 
210 
380 
450 
1265 
6500 
1600 
33 
20 
10 
25 
105 
210 
260 
345 
130 
171 
165 
120 
175 
129 
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endocrine disorders are displayed in tables 1 and 2. 
They agree well with those reported by others using 
different techniques [4, 51. The mean value obtained 
in normal pubertal and adult males was 612 t 172 
ng/lOO ml (n=lO), while a compiled average from the 
literature [S] is 670 f 230 ng/lOO ml. The highest 
figure was obtained for adrenal venous blood from a 
patient with virilizing adrenal adenoma (6500 ng/lOO 
ml, patient No. 8, table 2). High values were also 
found in untreated patients suffering from congential 
adrenal hyperplasia due to a 2 1 -hydroxylase deficiency 
and from idiopathic precocious puberty. In the latter 
condition, there was, in one case studied, a definite 
reduction of the level during treatment with cypro- 
terone acetate. Low values were obtained in an adult, 
unsubstituted castrate male, in a boy with congenital 
anorchia, and in one child with a congenital defect of 
testosterone biosynthesis (17,20-desmolase deficiency, 
proven by incubation of testicular tissue with testo- 
sterone precursors [6] ). Moderately low levels were 
found in cases with benign delayed puberty, Klinefelter’s 
syndrome, and hypogonadism, as one would expect. 
4. Discussion 
The competitive protein binding technique for the 
assay of hormones in biological fluids was introduced 
by Ekins (1960) for thyroxin [7]. Subsequently, 
Murphy [8,9] adapted the principle for the estimation 
of steroids. A large number of methods for the deter- 
mination of various steroids using CPB has since been 
published (for references and discussion see [lo]. 
These techniques have the advantage of relative sim- 
plicity and high sensitivity. Their specificity, however, 
depends on the prepurification steps applied rather 
than on the CPB itself. 
Among other difficulties, one of the major problems 
of CPB techniques is the separation of the free from 
the protein bound steroid fraction. For this purpose, 
various methods have been used, including gel filtra- 
tion (Sephadex G25 [l 11, dextrane coated charcoal 
[ 121, ammonium sulfate for protein precipitation 
[13], and Florisil, p.e. [2, 14, 151). We have, in the 
Dept. of Pediatrics, been previously using a modifica- 
tion of the relatively simple and non-specific method 
of Anderson [2] for the determination of “testoster- 
one-like” substances in plasma, where no prepurifica- 
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tion is carried out and the separation of the free from 
the bound fraction is done with Florisil. Our modifi- 
cations consisted of extraction with methylene 
chloride instead of ether (lower non-specific “reagent” 
blank, cf. [3]), of a different CPB step, cf. [ 161, and 
of minor changes of shaking. 
Although for clinical use, the results obtained with 
this previous method agreed well with those of urinary 
steroid determinations in the same subjects by highly 
specific gas chromatographic techniques (Zachmann 
[ 17]), the separation step with Florisil was a constant 
source of difficulties and did impair the reproducibili- 
ty of the calibration curves due to its sensitivity to 
even minimal changes of shaking time and other 
methodological factors. In addition, in our experience 
and in that of others [9, 151, too high testosterone 
values were obtained with Florisil in plasma samples 
from prepubertal children and females, and the water 
blanks were relatively high. 
Similar difficulties had been encountered in the 
CPB assays of CAMP and had been overcome by the 
use of relatively very stable, Sepharose-linked CAMP 
binding proteins [ 11. The results presented in this 
paper show that analogous improvements can be 
achieved for steroid assays with the help of immobil- 
ized binding proteins. The advantages c
+ 
sist in: 
i) rapid and facile separation of bound and free steroid 
fractions by simple filtration, ii) the constant equilib- 
rium between 20 min and at least 3 hr, resulting in 
improved reproducibility of the standard curves and 
relative insensitivity to changes in handling times, 
iii) reduction of the water blank, iv) no observable 
desorption of testosterone during filtration and 
washing procedures, v) the negligible nonspecific 
adsorption of testosterone to Sepharose and polyester 
net, and vi) the stability of the Sepharose-linked 
protein. 
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